We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Halting Drop of Blood Pressure During Septic Shock

By HospiMedica staff writers
Posted on 05 Sep 2000
A study has found that administering a superoxide dismutase (SOD) mimetic to a rat model of septic shock can remove excess superoxide free radicals, restoring the ability of norepinephrine to constrict blood vessels and reverse hypotension. More...
The study, conducted by researchers from the Saint Louis University School of Medicine (MO, USA) and MetaPhore Pharmaceuticals (St. Louis, MO, USA; www.metaphore.com), was reported in the August 15 issue of Proceedings of the National Academy of Sciences.

The researchers confirmed that free radicals--particularly superoxide anions--produced in large quantities during septic shock deactivate dopamine, norepinephrine, and epinephrine, destroying their biologic activity and often leading to a life-threatening free fall in blood pressure. The standard treatment is antibiotic therapy and intravenous fluids and catecholamines such as dopamine and norepinephrine to prevent a fall in blood pressure. However, the additional catecholamines administered are often destroyed by the huge excess of superoxide free radicals, produced as the body fights infection.

The SOD mimetic (M40403) is a specially constructed manganese-based compound developed by MetaPhore. Unlike the natural enzyme it simulates, MetaPhore's SOD is well-suited for use as a drug because it has a low molecular weight, as well as considerable oxidative and kinetic stability. According to MetaPhore, the SOD mimetics family has also shown promise in treating inflammation, pain, cancer, rheumatoid arthritis, and reperfusion injury and stroke.

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.